Eyenovia (NASDAQ:EYEN – Get Free Report)‘s stock had its “neutral” rating reaffirmed by equities researchers at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $2.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 38.89% from the stock’s previous close.
Eyenovia Price Performance
Shares of NASDAQ EYEN opened at $1.44 on Friday. Eyenovia has a fifty-two week low of $1.31 and a fifty-two week high of $124.80. The stock has a market cap of $2.01 million, a price-to-earnings ratio of -0.02 and a beta of 1.29. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.55 and a current ratio of 0.74. The firm’s 50-day simple moving average is $2.81 and its 200 day simple moving average is $18.28.
Institutional Investors Weigh In On Eyenovia
An institutional investor recently raised its position in Eyenovia stock. Geode Capital Management LLC lifted its stake in shares of Eyenovia, Inc. (NASDAQ:EYEN – Free Report) by 3.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 577,393 shares of the company’s stock after purchasing an additional 19,399 shares during the period. Geode Capital Management LLC owned 41.54% of Eyenovia worth $84,000 at the end of the most recent quarter. Institutional investors own 25.84% of the company’s stock.
Eyenovia Company Profile
Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.
Featured Articles
- Five stocks we like better than Eyenovia
- What to Know About Investing in Penny Stocks
- Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?
- Conference Calls and Individual Investors
- Lucid’s Stock Comeback—Is a Long-Term Recovery Ahead?
- Stock Market Sectors: What Are They and How Many Are There?
- BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.
